The Latest Breaking News from DGX

Despite Bio-Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Quest Diagnostics has outperformed the broader healthcare sector over the past year. Moreover, Wall Street analysts remain moderately optimistic about its prospects.

Although Quest Diagnostics has underperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Despite Waters’ weak performance relative to the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Quest Diagnostics Inc (NYSE:DGX) may be encountering what you might call a post-earnings digestion dance. Initially, DGX stock jumped higher, perhaps due to the algorithms and retail traders responding in unison to the better-than-expected results for the second quarter. But the next day, the security slipped, possibly as fund managers…

Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

While DGX stock has been hammered in the market recently, the smart money may be sensing a bounce-back opportunity.

Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.